Overview
PBYI market data
Price History
PBYI price chart
Valuation & Profitability
- P/E (TTM)
- 18.65 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.61 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.24 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 10.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.30 – $9.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $454.9M · P/B 2.30 · P/S 2.00.
Company News
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6Benzinga · Aug 7, 2026, 9:08 PM
Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M EstBenzinga · Aug 6, 2026, 8:40 PM
Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M EstBenzinga · Aug 6, 2026, 8:40 PM
Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M EstimateBenzinga · Aug 6, 2026, 8:09 PM